Effects of Royal Jelly Peptide on Motor Ability and Gene Expression in Zebrafish Model of Alzheimer's Disease

LIU Juncai; GE Zhen; JIANG Xiao; CUI Baojin; ZHANG Ping; SUN Jian'an; MAO Xiangzhao

doi:10.13386/j.issn1002-0306.2023010021

Volume 44 Issue 21

Oct. 2023

Turn off MathJax

Article Contents

Abstract

References

Science and Technology of Food Industry > 2023 > 44(21): 395-401. > DOI: 10.13386/j.issn1002-0306.2023010021

LIU Juncai, GE Zhen, JIANG Xiao, et al. Effects of Royal Jelly Peptide on Motor Ability and Gene Expression in Zebrafish Model of Alzheimer's Disease[J]. Science and Technology of Food Industry, 2023, 44(21): 395−401. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2023010021.

Citation:

PDF (1838 KB)

Effects of Royal Jelly Peptide on Motor Ability and Gene Expression in Zebrafish Model of Alzheimer's Disease

1.
College of Food Science and Engineering, Ocean University of China, Qingdao 266003, China
2.
College of Medical, Qingdao Binhai University, Qingdao 266404, China
3.
Shandong Fengcai Health Industry Co., Ltd., Weifang 262612, China

More Information

Received Date: January 03, 2023
Available Online: September 05, 2023

Graphical Abstract

Abstract

Abstract

Objective: Investigation of the trait improvement impact of royal jelly enzymatic products (royal jelly peptides) on Alzheimer's disease (AD) model zebrafishes. Methods: 150 wild-type AB strain zebrafishes (4 days after fertilization, 4 dpf) were randomly divided into normal group, model control group, donepezil hydrochloride positive control group (3.33 μg/mL), royal jelly enzymatic digest lyophilized powder-1 group (LPR-1, 1000 μg/mL) and royal jelly enzymatic digest lyophilized powder-2 group (LPR-2, 1000 μg/mL), and these groups were added in 6-well plates, respectively. The volume of each well was 3 mL, and 30 tails of zebrafishes were employed in each group. Except for the normal group, zebrafishes in other groups were treated with aluminum chloride hexahydrate (180 μmol/L) to establish AD models. The efficacy of recovery of motor dysfunction, improvement of responsiveness, inhibition of acetylcholinesterase (AchE) and inhibition of apoptosis were evaluated for each experimental group after treated with corresponding drugs simultaneously for 24 h. The relative expressions of TNF-α, caspase-3 and BDNF genes were also calculated and their effects on related genes were analyzed. Results: Compared to the model control group, the LPR-1 and LPR-2 administration groups zebrafishes showed prolonged total locomotor distance (highly significant, P<0.01), the differential speed of light and dark motion per minute (P<0.001) and the relative expression of BDNF gene (P<0.001) were significantly increased. Acetylcholinesterase (AchE) fluorescence values (extremely significant, P<0.001) and brain apoptotic cell fluorescence intensity (highly significant, P<0.01) were decreased, and the relative expression of TNF-α gene (highly significant, P<0.01) and caspase-3 gene (significant, P<0.05) were also decreased. Conclusion: Both of LPR-1 and LPR-2 have anti-Alzheimer's disease efficacy, and have potential for the development of functional foods for the prevention or treatment of Alzheimer's disease.
- royal jelly peptide,
- zebrafish,
- Alzheimer's disease,
- behavioral analysis,
- motor dysfunction,
- acetylcholinesterase,
- brain apoptosis,
- relative gene expression

FullText(HTML)

References (31)

References

[1]	DUBOIS B, FELDMAN H H, JACOVA C, et al. Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria[J]. The Lancet Neurology,2014,13(6):614−629. doi: 10.1016/S1474-4422(14)70090-0
[2]	OSSENKOPPELE R, PIJNENBURG Y a L, PERRY D C, et al. The behavioural/dysexecutive variant of Alzheimer's disease: Clinical, neuroimaging and pathological features[J]. Brain,2015,138(9):2732−2749. doi: 10.1093/brain/awv191
[3]	JESSEN F, AMARIGLIO R E, VANBOXTEL M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease[J]. Alzheimers Dement,2014,10(6):844−52. doi: 10.1016/j.jalz.2014.01.001
[4]	SCHELTENS P, BLENNOW K, BRETELER M, et al. Alzheimer's disease[J]. The Lancet,2016,388(10043):505−517. doi: 10.1016/S0140-6736(15)01124-1
[5]	ZHANG X X, TIAN Y, WANG Z T, et al. The epidemiology of Alzheimer's disease modifiable risk factors and prevention[J]. J Prev Alzheimers Dis,2021,8(3):313−321.
[6]	SELKOE D J, HARDY J. The amyloid hypothesis of Alzheimer's disease at 25 years[J]. EMBO Mol Med,2016,8(6):595−608. doi: 10.15252/emmm.201606210
[7]	ALI A M, KUNUGI H. Royal jelly as an intelligent anti-aging agent-a focus on cognitive aging and Alzheimer's disease: A review[J]. Antioxidants (Basel),2020,9(10):937, 2−46.
[8]	KAWAHATA I, XU H, TAKAHASHI M, et al. Royal jelly coordinately enhances hippocampal neuronal expression of somatostatin and neprilysin genes conferring neuronal protection against toxic soluble amyloid- β oligomers implicated in Alzheimer's disease pathogenesis[J]. Journal of Functional Foods,2018,51:28−38. doi: 10.1016/j.jff.2018.10.006
[9]	PAN Y, XU J, CHEN C, et al. Royal jelly reduces cholesterol levels, ameliorates abeta pathology and enhances neuronal metabolic activities in a rabbit model of Alzheimer's disease[J]. Front Aging Neurosci,2018,10:50. doi: 10.3389/fnagi.2018.00050
[10]	YOU M, PAN Y, LIU Y, et al. Royal jelly alleviates cognitive deficits and beta-amyloid accumulation in APP/PS1 mouse model via activation of the cAMP/PKA/CREB/BDNF pathway and Inhibition of neuronal apoptosis[J]. Front Aging Neurosci,2018,10:428.
[11]	GUARDIA DE SOUZA E S T, DO VAL DE PAULO M E F, DA SILVA J R M, et al. Oral treatment with royal jelly improves memory and presents neuroprotective effects on icv-STZ rat model of sporadic Alzheimer's disease[J]. Heliyon,2020,6(2):e03281. doi: 10.1016/j.heliyon.2020.e03281
[12]	WANG X. Royal jelly promotes DAF-16-mediated proteostasis to tolerate B-amyloid toxicity in C. elegans model of Alzheimer's disease[J]. Oncotarget,2016,7:54183−54193. doi: 10.18632/oncotarget.10857
[13]	RIBARIC S. Peptides as potential therapeutics for Alzheimer's disease[J]. Molecules,2018,23(2):283.
[14]	SUGIMOTO H. Donepezil hydrochloride: A treatment drug for Alzheimer's disease[J]. The Chemical Record,2001,1(1):63−73. doi: 10.1002/1528-0691(2001)1:1<63::AID-TCR9>3.0.CO;2-J
[15]	SUGIMOTO H, OGURA H, ARAI Y, et al. Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor[J]. Jpn J Pharmacol,2002,89(1):7−20. doi: 10.1254/jjp.89.7
[16]	RELKIN N R. Beyond symptomatic therapy: A re-examination of acetylcholinesterase inhibitors in Alzheimer's disease[J]. Expert Review of Neurotherapeutics,2014,7(6):735−748.
[17]	ZHANG H Y, YAN H, Tang X C. Non-cholinergic effects of huperzine A: Beyond inhibition of acetylcholinesterase[J]. Cell Mol Neurobiol,2008,28(2):173−183. doi: 10.1007/s10571-007-9163-z
[18]	任擎宇, 靳梦, 商学良, 等. 基于网络药理学和斑马鱼模型的金盏菊缓解阿尔茨海默病症状及作用机制[J]. 中国药理学通报,2022,38(3):429−436 REN Q Y, JIN M, SHANG X L, et al. Study on anti-Alzheimer's disease activity and underlying mechanism of Calendula officinalis L. based on network pharmacology and zebrafish model[J]. Chinese Pharmacological Bulletin,2022,38(3):429−436.
[19]	MIAO W, HE L, ZHANG T, et al. Lentinan impairs the early development of zebrafish embryos, possibly by disrupting glucose and lipid metabolism[J]. Processes,2022,10(1):120. doi: 10.3390/pr10010120
[20]	NISHIMURA I, UETSUKI T, KUWAKO K, et al. Cell death induced by a caspase-cleaved transmembrane fragment of the Alzheimer amyloid precursor protein[J]. Cell Death and Differentiation,2002,9(2):199−208. doi: 10.1038/sj.cdd.4400931
[21]	AZMAN K F, ZAKARIA R. Recent advances on the role of brain-derived neurotrophic factor ( BDNF) in neurodegenerative diseases[J]. Int J Mol Sci,2022,23(12):6827, 2−24.
[22]	STEHLY G R, GINGERICH W H. Evaluation of AQUI-STM (efficacy and minimum toxic concentration) as a fish anaesthetic/sedative for public aquaculture in the United States[J]. Aquaculture Research,1999,30(5):365−372. doi: 10.1046/j.1365-2109.1999.00339.x
[23]	DREWS H J, KLEIN R, LOURHMATI A, et al. Losartan improves memory, neurogenesis and cell motility in transgenic Alzheimer's mice[J]. Pharmaceuticals (Basel),2021,14(2):166.
[24]	GUNTHER A, LUCZAK V, ABEL T, et al. Caspase-3 and GFAP as early markers for apoptosis and astrogliosis in shRNA-induced hippocampal cytotoxicity[J]. J Exp Biol,2017,220(Pt 8):1400−1404.
[25]	董斌. 阿尔兹海默症药物研究进展[J]. 化工设计通讯,2020,46(4):221−222 DONG B. Research progress in Alzheimer's drugs[J]. Chemical Engineering Design Communications,2020,46(4):221−222.
[26]	SANG Z, WANG K, SHI J, ET AL. Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer's disease[J]. Eur J Med Chem,2020,187:111958. doi: 10.1016/j.ejmech.2019.111958
[27]	王昊, 赵振宇, 沈霞, 等. 基于系统药理学研究远志治疗阿尔茨海默病的作用机制[J]. 药学学报,2017,52(10):1554−1561 doi: 10.16438/j.0513-4870.2017-0541 WANG H, ZHAO Z Y, SHEN X, et al. System pharmacology-based study on mechanism of polygala radix in the treatment of Alzheimer's disease[J]. Acta Pharm Sin,2017,52( 10):1554−1561. doi: 10.16438/j.0513-4870.2017-0541
[28]	HADIPOUR M, MEFTAHI G H, AFARINESH M R, et al. Crocin attenuates the granular cells damages on the dentate gyrus and pyramidal neurons in the CA3 regions of the hippocampus and frontal cortex in the rat model of Alzheimer's disease[J]. J Chem Neuroanat,2021,113:101837. doi: 10.1016/j.jchemneu.2020.101837
[29]	GHAVAMI S, HASHEMI M, ANDE S R, et al. Apoptosis and cancer: Mutations within caspase genes[J]. J Med Genet,2009,46(8):497−510. doi: 10.1136/jmg.2009.066944
[30]	ZAFEER M F, FIRDAUS F, ANIS E, et al. Prolong treatment with trans-ferulic acid mitigates bioenergetics loss and restores mitochondrial dynamics in streptozotocin-induced sporadic dementia of Alzheimer's type[J]. Neurotoxicology,2019,73:246−257. doi: 10.1016/j.neuro.2019.04.006
[31]	王玥, 王旭, 于嵩, 等. 阿魏酸对阿尔茨海默病转基因小鼠脑内氧化应激和凋亡相关蛋白的影响[J]. 天然产物研究与开发,2017,29(5):762−766 doi: 10.16333/j.1001-6880.2017.5.007 WANG Y, WANG X, YU S, et al. Effects of ferulic acid on oxidative stress and apoptosis related proteins in Alzheimer's disease trans-genic mice[J]. Nat Prod Res Dev,2017,29(5):762−766. doi: 10.16333/j.1001-6880.2017.5.007